Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosmo Announces Submission of Winlevi® to the European Medicines Agency (EMA)
Details : Winlevi (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age & older.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Adalvo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo & Adalvo Sign Supply Deal for Rifamycin SV MMX® 200MG Across Key Global Regions
Details : Under the licensing agreement, Adalvo will receive from Cosmo the exclusive right to develop and commercialize Rifamycin SV MMX (rifamycin sodium) for the treatement of Travelers’ Diarrhea.
Product Name : Rifamycin SV MMX
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 04, 2023
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Adalvo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Dr. Falk Pharma
Deal Size : Undisclosed
Deal Type : Termination
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
Details : Cosmo terminates mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX (Rifamycin Sodium) in the EU and other selective countries.
Product Name : Rifamycin SV MMX
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 04, 2023
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Dr. Falk Pharma
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosmo Begins Phase III Trials for Androgenetic Alopecia in Males
Details : CB-03-01 (clascoterone) solution is an androgen receptor inhibitor which is currently being evaluated for the treatment of patients with androgenetic alopecia.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Hyundai Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Details : Under the license agreement terms, Hyundai Pharm will receive from Cosmo, the exclusive right to commercialize Winlevi (clascoterone) in the Republic of Korea, which is indicated for acne vulgaris.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Hyundai Pharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cosmo and Hikma Sign License for Winlevi® in 17 Middle East and North Africa Countries
Details : Under the terms of the agreement, Hikma will receive from Cosmo, the exclusive right to register and commercialize Winlevi (clascoterone) in African countries, which is indicated for acne vulgaris.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : $0.7 million
February 10, 2023
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Hyphens Pharma
Deal Size : $5.0 million
Deal Type : Licensing Agreement
Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia
Details : WINLEVI (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : $1.0 million
December 21, 2022
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Hyphens Pharma
Deal Size : $5.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosmo Announces FDA Grants Orphan-Drug Designation of Rifamycin for Treatment of Pouchitis
Details : Rifamycin SV (rifamycin sodium) is a DNA-directed RNA polymerase inhibitor antibiotic, being evaluated for the treatement of pouchitis.
Product Name : Rifamycin SV
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : 3S Bio Inc
Deal Size : $70 million
Deal Type : Licensing Agreement
Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
Details : Under the terms of the License agreement, 3SBio will receive from Cosmo the exclusive right to develop and commercialize Winlevi (clascoterone) in Greater China, which is indicated for acne vulgaris.
Product Name : Winlevi
Product Type : Steroid
Upfront Cash : $6.5 million
July 28, 2022
Lead Product(s) : Clascoterone
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : 3S Bio Inc
Deal Size : $70 million
Deal Type : Licensing Agreement
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosmo Gets Marketing Authorization for Rifamycin SV MMX (Stadmycin™) in Italy from AIFA
Details : Stadmycin (rifamycin sodium) is a DNA-directed RNA polymerase inhibitor antibiotic, indicated for the treatement of Travelers’ Diarrhea.
Product Name : Stadmycin
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 08, 2022
Lead Product(s) : Rifamycin Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable